ESALF News and Press, Eisai Co Ltd From 04/06/23

2023-04-06 12:35:54 ET FDA’s accelerated drug approval program came under scrutiny on Thursday after the agency withdrew its approval for Makena, a drug first cleared the regulatory hurdle more than a decade ago to prevent preterm birth in women. The FDA approved Makena in 2011 u...

2023-04-03 07:05:32 ET The U.S. National Institute on Aging (NIA) is funding an up to $300M project to create a research database for Alzheimer's disease (AD) which can track Americans' health for many years and help researchers to get insights on AD, Reuters reported. The NIA plan...

2023-03-14 05:42:41 ET Medivir ( OTC:MVRBF ) said the first patient with liver cancer started treatment with its drug fostroxacitabine bralpamide (fostrox) in combination with Eisai's ( OTCPK:ESALF ) ( OTCPK:ESAIY ) Lenvima in phase 2a trial. In the Swedish c...

2023-03-06 04:34:16 ET The U.S. Food and Drug Administration (FDA) granted priority review to Biogen's ( NASDAQ: BIIB ) application seeking traditional approval of Alzheimer's disease (AD) therapy Leqembi (lecanemab) from its current status of accelerated approval. ...

Reata Pharmaceuticals ( NASDAQ: RETA ) lost ~32% on Monday to reach the lowest level in over four months as a key FDA official leaves the agency while the company awaits the U.S. approval for its Friedreich's ataxia ((F.A.)) therapy, omaveloxolone. Earlier in the day, multiple new...

Summary Growth in Japan markets the standout for the period, with growth across all core segments. Leqembi gaining substantial traction in regulatory approvals in key global markets. Hence therein lies a strong investment opportunity with ESALF for those seeking exposure to breakthr...

The U.S. CEO of Eisai ( OTCPK:ESALY ) said that the U.S. FDA could grant full approval of its Alzheimer's treatment Leqembi (lecanemab) as soon as July. Speaking with CNBC, Ivan Cheung said, "We’re literally talking about maybe like five months away, so we are moving with urgency d...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The search for  growth stocks , or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings back into their core bu...

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 06, 2023 03:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice President, Chief Financial Officer, Chief IR Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, Presiden...

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Eisai Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation